Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Troubled Biotechs: Intercytex, Vanda, Advanced Life Sciences

This article was originally published in The Pink Sheet Daily

Executive Summary

With disappointing data from its lead program, the UK’s InterCytex is considering all options, including merger. In the U.S., Vanda is facing shareholder activism while Advanced Life Sciences is in the odd position of not being able to afford good news from FDA.
Advertisement

Related Content

Troubled Biotechs: Orexigen, Telik, Trubion
Troubled Biotechs: Orexigen, Telik, Trubion
Vanda’s Fanapt Approval Is FDA U-Turn
Vanda’s Fanapt Approval Is FDA U-Turn
Investor Sigma-Tau Takes Another Slice of RegeneRx Pie
Proxy War-Front Latest: Amylin, Vanda Rocked By Dissident Shareholders
Lilly's mGlu2/3 Agonist Fails In Phase II For Schizophrenia
Lilly’s mGlu2/3 Agonist Fails In Phase II For Schizophrenia – But So Does Zyprexa
Biotech Is Headed Toward A Cliff In 2009, Finance Experts Predict
Biotech Is Headed Toward A Cliff In 2009, Finance Experts Predict

Topics

Advertisement
UsernamePublicRestriction

Register

PS069042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel